Clinical outcomes are complex and often involve multiple systemic burdens. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory testing and pathological activation.
The platform can help match the needs of a team of authoritative experts at home and abroad to provide accurate diagnostics and treatment regimens. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat blood tumour diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to changes in the condition.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of the re-arrangement of HL along with IgH. The platform serves a team of internationally authoritative experts in the field of blood tumours in China, providing the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.